Kiadehi Fatemeh Babaee, Samani Pegah, Barazandeh Sanaz, Pam Pedram, Hajipour Ali, Goli Narges, Asadi Ali
Department of Clinical Nutrition, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Nutrition and Food Security Research Center, Shahid Sadoughi University of Medical Science, Yazd, Iran.
Curr Ther Res Clin Exp. 2024 Dec 31;102:100772. doi: 10.1016/j.curtheres.2024.100772. eCollection 2025.
Patients with metabolic disorders benefit from using anthocyanins. Nevertheless, the findings drawn from extant trials remain contentious. Thus, this meta-analysis evaluated anthocyanin's effect on inflammatory biomarkers in patients with metabolic disorders.
We comprehensively searched electronic databases, including PubMed, Scopus, Web of Science, and CENTRAL, from their inception to June 14, 2024.
A total of 11 randomized controlled clinical trials with 14 arms were analyzed. There was no significant effect of anthocyanin supplementation on interleukin (IL)-1β levels (standardized mean difference [SMD] = -0.01, 95% CI: -0.33, 0.31; = 0.941, = 62.4%, = 0.031), tumor necrosis factor-α (TNF-α) (SMD = -0.49, 95% CI: -1.07, 0.09; = 0.098, = 94.0%, < 0.001) and IL-6 (SMD = -0.69, 95% CI: -1.45, 0.06; = 0.073, = 95.2%, < 0.001), respectively. A significant between-study heterogeneity was identified, which was reduced when subgrouping by sample size, dosage, and study population. However, subgroup analysis showed that it might decrease TNF-α and IL-6 in patients with hypertension, and if the intervention lasted less than 12 weeks.
There was no significant impact of anthocyanin supplementation on IL-1β, TNF-α, and IL-6; however, it should be noted that the intervention has a decreasing impact on individuals with hypertension. Our observed effect sizes on IL-1β, TNF-α, and IL-6 are not clinically important.
患有代谢紊乱的患者可从使用花青素中获益。然而，现有试验得出的结果仍存在争议。因此，本荟萃分析评估了花青素对代谢紊乱患者炎症生物标志物的影响。
我们全面检索了电子数据库，包括PubMed、Scopus、Web of Science和CENTRAL，检索时间从各数据库建库至2024年6月14日。
共分析了11项随机对照临床试验的14个分支。补充花青素对白细胞介素（IL）-1β水平（标准化均数差[SMD]=-0.01，95%可信区间：-0.33，0.31；I²=0.941，P=62.4%，P=0.031）、肿瘤坏死因子-α（TNF-α）（SMD=-0.49，95%可信区间：-1.07，0.09；I²=0.098，P=94.0%，P<0.001）和IL-6（SMD=-0.69，95%可信区间：-1.45，0.06；I²=0.073，P=95.2%，P<0.001）均无显著影响。研究间存在显著异质性，按样本量、剂量和研究人群进行亚组分析后异质性降低。然而，亚组分析表明，在高血压患者中，若干预持续时间少于12周，花青素可能会降低TNF-α和IL-6水平。
补充花青素对IL-1β、TNF-α和IL-6无显著影响；然而，应注意的是，该干预对高血压患者的影响呈下降趋势。我们观察到的IL-1β、TNF-α和IL-6的效应量在临床上并不重要。
